

Cognitive Impairment and Celiac Disease

William T. Hu, MD, PhD; Joseph A. Murray, MD; Melanie C. Greenaway, PhD;
Joseph E. Parisi, MD; Keith A. Josephs, MST, MD

Objective: To characterize the clinical, radiological, and electrophysiological laboratory profiles and histological features of patients who developed cognitive impairment temporally associated with celiac disease.

Design: Case series.

Setting: Referral center.

Patients: Patients with the onset of progressive cognitive decline within 2 years of symptomatic onset or with a severe exacerbation of biopsy-proved adult celiac disease were identified from the Mayo Clinic medical records from January 1, 1970, to December 31, 2005. Patients were excluded if an alternate cause of their cognitive impairment was identified.

Results: Thirteen patients (5 women) were identified. The median age at cognitive impairment onset was 64 years (range, 45-79 years), which coincided with symptom onset or exacerbation of diarrhea, steatorrhea, and abdominal cramping in 5 patients. Amnesia, acalculia, confusion, and personality changes were the most common presenting features.

The average initial Short Test of Mental Status score was 28 of a total of 38 (range, 18-34), which was in the moderately impaired range. The results of neuropsychological testing suggested a trend of a frontosubcortical pattern of impairment. Ten patients had ataxia, and 4 of them also had peripheral neuropathy. Magnetic resonance imaging of the head showed nonspecific T2 hyperintensities, and electroencephalography showed nonspecific diffuse slowing. Deficiencies in folate, vitamin B₁₂, vitamin E, or a combination were identified in 4 patients, yet supplementation did not improve their neurological symptoms. Three patients improved or stabilized cognitively with gluten withdrawal. A detailed histological analysis revealed nonspecific gliosis.

Conclusions: A possible association exists between progressive cognitive impairment and celiac disease, given the temporal relationship and the relatively high frequency of ataxia and peripheral neuropathy, more commonly associated with celiac disease. Given the impact for potential treatment of similar cases, recognition of this possible association and additional studies are warranted.

Arch Neurol. 2006;63:1440-1446

CELIAC DISEASE (CD) IS A multiorgan systemic disease that most commonly affects the gut but also affects other organs, especially the skin. Up to 10% of patients with CD and gastrointestinal symptoms have otherwise unexplained neurological symptoms,¹ and neurological involvement of CD is one proposed cause. Neurological symptoms can occur at or near the onset of gastrointestinal complaints in patients newly diagnosed as having adult-onset CD or may occur during adulthood in patients with childhood-onset CD. Ataxia, peripheral neuropathy, and seizures are neurological complications most commonly associated with CD.^{2,3} Dementia temporally associated with adult-onset CD has only been previously reported in 6 patients,^{4,5} with additional cognitive impairment reported in 7 others,^{2,6,7} and the association between cognitive deficits and adult-onset CD remains contentious. We identified 13 patients from our institution's medical records who had close temporal onset of gastrointestinal symptoms and cognitive impairment associated with CD. Herein, we review the clinical features, laboratory findings, mag-

netic resonance imaging (MRI) results, electroencephalographic (EEG) results, neuropsychological profiles, and clinical outcomes of these patients, who all had biopsy-proved CD and otherwise unexplained cognitive impairment. We also perform detailed neuropathological analysis on 5 patients who either underwent a brain biopsy or a postmortem examination.

METHODS

CLINICAL FINDINGS

Mayo Clinic medical records from January 1, 1970, to December 31, 2005, were electronically searched using terms for CD (*celiac disease, celiac sprue, nontropical sprue, and gluten-sensitive enteropathy*) and encephalopathy (*cognitive impairment, dementia, and encephalopathy*). Fifty patients for whom both search terms matched were identified. The historical records of all 50 patients were reviewed to exclude all patients without biopsy-proved CD or patients in whom an alternate cause of dementia was identified. Patients were excluded if they fulfilled the diagnostic criteria for delirium as specified in the *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)*.⁸ Eighteen patients met the

Author Affiliations:

Departments of Neurology (Drs Hu and Josephs), Internal Medicine (Division of Gastroenterology) (Dr Murray), Psychology (Dr Greenaway), and Laboratory Medicine and Pathology (Dr Parisi), Mayo Clinic College of Medicine, Rochester, Minn.

Table 1. Clinical Characteristics of Patients With CD and Cognitive Impairment

Patient No./Sex	Age at Cognitive Decline, y	Dementia Features	Age at GI Symptom Onset, y	Type of GI Symptoms	Supportive CD Features	Lag Time Between Cognitive and GI Symptoms, y	Survival After Cognitive Decline, y
1/M	59	Amnesia, confusion, and personality change	59	Diarrhea	None	0	3
2/F	60	Amnesia, personality change, and apraxia	60	Steatorrhea and low albumin level	DH	0	4
3/M	64	Amnesia, confusion, and personality change	64	Steatorrhea and weight loss	None	0	Alive at the age of 81 y; improved, but began to deteriorate when not eating a gluten-free diet
4/F	73	Amnesia, confusion, and acalculia	73	Diarrhea	AGA, AGG, and TTG	0	Alive and stable at the age of 74 y
5/M	79	Amnesia, disorientation, and acalculia	79	Weight loss and anemia	AGA, AGG, EMA, and TTG	0	Alive but deteriorating at the age of 82 y
6/M	61	Amnesia, disorientation, personality change, and acalculia	60	Weight loss, fatigue, diarrhea, and steatorrhea	TTG	1	1
7/M	45	Confusion and disorientation	47	Loose stool and weight loss	None	2	6
8/F	52	Amnesia, personality change, aphasia, acalculia, and dysgraphia	50	Weight loss	DH	2	5
9/M	54	Amnesia	56	Loose stool	None	2	Alive; improved and stable until AD at the age of 73 y
10/M	65	Amnesia, confusion, disorientation, acalculia, and dysgraphia	63	Diarrhea	DH	2	9
11/F	70	Amnesia	72	Nausea and abdominal distention	DH	2	11
12/F	72	Amnesia, confusion, disorientation, personality change, and acalculia	74	Anemia	None	2	8
13/M	74	Amnesia and acalculia	72	Constipation and diarrhea	AGA and DH	2	6

Abbreviations: AD, Alzheimer disease; AGA, antigliadin IgA; AGG, antigliadin immunoglobulin G; CD, celiac disease; DH, dermatitis herpetiformis; EMA, endomysial antibody; GI, gastrointestinal; TTG, tissue transglutaminase IgA.

previously described inclusion and exclusion criteria. We further excluded any patient whose onset of cognitive symptoms (self- or family-reported) occurred more than 2 years before or after development of gastrointestinal symptoms associated with a first-time diagnosis of CD or an exacerbation of biopsy-proved adult-onset CD. Five patients had longer time lapses between the onset of gastrointestinal and neurological symptoms (3, 3, 4, 6, and 7 years). Available clinical information for the 13 remaining patients, including cognitive profiles, noncognitive neurological findings, computed tomographic or MRI findings of the brain, EEG findings, laboratory data, neuropsychological profiles, and clinical outcomes, was reviewed.

NEUROPATHOLOGICAL STUDIES

Two patients (patients 2 and 7) underwent a right frontal lobe brain biopsy, and 3 (patients 1, 6, and 8) underwent postmortem whole brain tissue examination. In the patients who underwent postmortem whole brain tissue examination, sections from frontal, temporal, parietal, and occipital cortices, and the amygdala, hippocampus, thalamus, basal ganglia, brainstem, and cerebellum, were analyzed. In all 5 patients, 5- μ m sections were stained with hematoxylin-eosin and modified Bielschowsky stain. In addition, all patients underwent immunohistochemical analysis with glial markers: glial fibrillary acid protein for astrocytes (polyclonal, 1:800; DAKO, Carpinteria,

Calif). Neuronal pathological features were studied with antibodies to neurofilament protein (NF-L, clone 2F11, 1:75; DAKO), ubiquitin (polyclonal, 1:100; DAKO), α -synuclein (clone LB509, 1:200; Zymed, San Francisco, Calif), and phospho- τ (clone AT8, 1:1000; Endogen, Woburn, Mass). Prion studies were also conducted (clone 3F4, 1:5; DAKO). Additional studies were performed on patient 6, including immunohistochemistry for CD45 and CD68 (phosphoglucomutase 1 antibodies), the Luxol fast blue stain, and reverse-transcription polymerase chain reaction for *Tropheryma whipplei*.

STATISTICAL ANALYSIS

In reviewing the Short Test of Mental Status scores,⁹ patients were divided into 2 groups: those with the onset of gastrointestinal and cognitive symptoms separated by 1 year or less, and those with the symptoms separated by more than 1 year. The *t* test was used to determine the difference in average scores between the 2 groups. The difference was considered statistically significant if *P* < .05.

RESULTS

CLINICAL

All 13 patients, 5 of whom were women, had a detailed description of their cognitive impairment (**Table 1**). The

Table 2. Findings From a Neurological Examination, EEG, a CSF Test, and a Metabolic Workup of Patients With CD and Cognitive Impairment

Patient No./Sex	Short Test of Mental Status Score*	Other Neurological Findings	EEG Findings	CSF Protein Level	CSF NSE Level	Nutritional Deficiency	Diagnosis
1/M	29	AT, HA, and SZ	Rhythmic δ , slowing in temporal regions, left side greater than right side	Normal	ND	None	Possible CJD; autopsy showed nonspecific gliosis
2/F	10†	AT and PN	Bitemporal slowing, right side greater than left side	Normal	ND	None	Cognitive impairment associated with CD; the biopsy specimen showed nonspecific gliosis
3/M	30	None	Low-amplitude β waves in bilateral anterior regions	Normal	ND	Carotene	None
4/F	23	AT	ND	ND	ND	None	Possible cognitive impairment associated with CD
5/M	18	AT	Mild diffuse θ slowing, maximal over the left temporal region	Normal	Normal	Folate, vitamin B ₁₂ , and vitamin D	Vitamin B ₁₂ deficiency
6/M	20	AT, MC, and PN	ND	Elevated (55 mg/dL)	High	Folate and vitamin E	CJD vs cognitive impairment associated with CD; autopsy showed nonspecific gliosis
7/M	ND	AT, MC, and SZ	Bifrontal δ slowing	Normal	ND	Folate and carotene	CJD vs cognitive impairment associated with CD; the biopsy specimen showed gliosis
8/F	28	HA and SZ	Bitemporal θ slowing	Normal	High	None	FTLD-U; autopsy showed neuronal loss with gliosis and ubiquitin-positive inclusions
9/M	34	AT and PN	Bifrontal slowing, δ slowing in the left temporal region, bilateral intermittent sharp waves in sleep	Elevated (58 mg/dL)	ND	Vitamin B ₁₂ and vitamin D	None
10/M	33	AT and MC	Normal	ND	ND	None	Possible cognitive impairment associated with CD
11/F	34	AT and HA	ND	ND	ND	Carotene and vitamin D	None
12/F	ND	None	Increase of symmetric bifrontal β activity	Normal	ND	None	None
13/M	ND	AT and PN	ND	Elevated (81 mg/dL)	ND	None	None

Abbreviations: AT, ataxia; CD, celiac disease; CJD, Creutzfeldt-Jakob disease; CSF, cerebrospinal fluid; EEG, electroencephalography; FTLD-U, frontotemporal lobar degeneration with ubiquitin-only immunoreactive changes; HA, headache; MC, myoclonus; ND, not done; NSE, neuron-specific enolase; PN, peripheral neuropathy; SZ, seizure.

*The total score possible was 38.

†This patient took the Mini-Mental State Examination instead; the total score possible was 30.

median self- or family-reported age at cognitive symptom onset was 64 years (age range, 45-79 years), with 5 patients developing simultaneous neurological and gastrointestinal symptoms (median age, 64 years; age range, 59-79 years). The median age at gastrointestinal complaint was 63 years (age range, 47-79 years), with diarrhea being the most common symptom. Five patients also had dermatitis herpetiformis. All small-bowel biopsy results showed partial or total villous atrophy consistent with CD, with no suggestions of other causes, including Whipple disease. Antigliadin antibodies (immunoglobulin A or immunoglobulin G) or tissue transglutaminase immunoglobulin A levels were positive for disease in all 4 patients tested. In patient 4, the serum tissue trans-

glutaminase titer increased from a premorbid level of 25.4 to 124.2 U at her neurological evaluation.

COGNITIVE IMPAIRMENT

Almost all patients had insidious subacute onset of their cognitive impairment. Three patients (patients 1, 6, and 7) had an initial rapidly progressive course. Of the 13 patients, the most common cognitive complaint was amnesia (n=12), followed by acalculia (n=7), confusion (n=6), and personality change (n=6) (Table 1). The Short Test of Mental Status was performed in 9 patients, with an average score of 28 of a total of 38 (range, 18-34) (Table 2). One patient scored 10 of 30 on the Mini-Mental State Ex-

Table 3. Neuropsychological Test Performance*

Neuropsychological Test	Patient No.				
	8	9	10	11	12
Intellectual function	WAIS-III	WAIS-R	WAIS-R†	WAIS-III	WAIS†
Verbal comprehension	67	120	95	118	64
Perceptual organization	62	120	90	89	78
Working memory (WAIS-III)	55	106‡§	NA	86	81‡
Processing speed (WAIS-III)	69	NA	NA	81	NA
Learning and memory	WMS-III	WMS-III	WMS	WMS-R	WMS
Paragraph learning	16	37	42	63	≤1
Paragraph retention	9	25	<5	9	<5
Visual learning (figures)	9¶	91	NA	63	NA
Visual retention	75¶	9	NA	37	NA
AVLT					
Word list learning	NA	10-19	<10	<10	NA
Word list retention	NA	80-85	<10	60-69	NA
Language					
Receptive (token test)	<1	NA	NA	60-71	NA
Expressive					
Boston Naming Test	2-6	NA	NA	41-59	NA
Letter fluency	<1	NA	NA	11-18	NA
Semantic fluency	1-2	NA	NA	11-18	NA
Visuoconstruction (Bender-Gestalt test)	Impaired	NA	Normal	Normal	NA

Abbreviations: AVLT, Rey Auditory Verbal Learning Test; NA, data not available; WAIS, Wechsler Adult Intelligence Scale; WAIS-R, WAIS-Revised; WAIS-III, WAIS-Third Edition; WMS, Wechsler Memory Scale; WMS-R, WMS-Revised; WMS-III, WMS-Third Edition.

*Because patients were seen clinically rather than for research purposes, neuropsychological test batteries varied. Normative data from the WAIS, WAIS-R, or WAIS-III were used for intellectual function, working memory, and processing speed and are presented as standard scores (mean, 100; SD, 15). Normative data from the Mayo's Older Americans Normative Studies were used for the remaining tasks (learning and memory, AVLT, language, and visuoconstruction) and are presented as percentiles.

†Scores reflect verbal and performance IQ from the WAIS or WAIS-R.

‡Freedom from distractibility from the WAIS or WAIS-R in keeping with the IQ test given.

§Subject also performed in the impaired range (<1 percentile) on the Stroop test.

||Overall immediate recall (memory quotient) and delayed retention from the WMS.

¶Patient received picture rather than figure memory.

amination.¹⁰ Patients with the onset of neurological symptoms within 1 year of gastrointestinal symptoms had a lower average Short Test of Mental Status score of 24, compared with an average of 32 among the rest ($P<.02$). There was no association between Short Test of Mental Status score and number of cognitive domains affected. Neuropsychological test results were available for 5 of the 13 patients (**Table 3**). Two patients (patients 9 and 11) had learning inefficiency, 1 (patient 10) had memory deficits more than learning inefficiency, and the other 2 (patients 8 and 12) had global cognitive impairment.

Surprisingly, 3 patients (patients 1, 6, and 7) were initially diagnosed as having possible Creutzfeldt-Jakob disease (CJD) because of a rapidly progressive course and the constellation of subacute dementia and ataxia, and myoclonus and seizure in 2 each. In addition, 4 patients (patients 2, 4, 6, and 7) were diagnosed as having "celiac dementia" during their evaluation.

ADDITIONAL FEATURES

Among complications known to be associated with CD, gait ataxia was the most common symptom (10 of 13 patients), followed by peripheral neuropathy, myoclonus, seizure, and headaches. All patients with peripheral neuropathy or myoclonus also had ataxia, and 1 patient had all 3 symptoms. Only 2 patients had cognitive impairment without other neurological symptoms.

TEST FINDINGS

Electroencephalography was performed in 9 patients, and showed focal or diffuse slowing in 6. Two patients had nonspecific frontal changes, and only 1 had a normal EEG result. Computed tomography of the head showed generalized atrophy in 4 patients (patients 7, 10, 11, and 12) and dense basal ganglia calcification in 1 (patient 11). Magnetic resonance imaging was performed in 7 patients and similarly showed generalized atrophy in 6 and frontal atrophy in 1 (**Figure 1**). On MRI, 3 types of changes were observed: confluent periventricular changes (Figure 1A), patchy cortical and subcortical areas of T2 hyperintensities (Figure 1B), and both (Figure 1C and D). In 1 patient, there were unilaterally increased T2 hyperintensities in the thalamus, with progression noted on subsequent MRI (Figure 1E and F).

Cerebrospinal fluid was obtained from 10 patients, and 2 had an elevated protein level. Because of clinical suspicion for a prion disease, neuron-specific enolase levels were obtained from 3 patients. Two patients had elevated levels of neuron-specific enolase, suggestive of CJD; the 14-3-3 level was tested in only 1 of these patients, and was normal.

Nutritional deficiency was identified in 6 patients (Table 2), including deficiencies of vitamin B₁₂ in 2 patients and of folate in 3 patients. The vitamin E level was checked in 3 patients and was low in 1. Two other pa-




Figure 1. Magnetic resonance imaging (MRI) findings of patients with celiac disease and cognitive impairment; fluid-attenuated inversion recovery images are shown. A, Confluent areas of periventricular T2 hyperintensities were seen in patient 4. B, Scattered foci of T2 hyperintensities involving bilateral subcortical regions were found in patient 9. C and D, Both types of MRI changes were found in patient 11. E and F, The temporal sequence of subcortical and thalamic changes in patient 6 revealed increased intensity in the subcortical lesion and expansion of the lesion in the left temporal lobe 4 months later.

tients were already receiving vitamin E supplementation. Five patients identified with deficiencies were treated with oral supplementation (folate or vitamin B₁₂, D, or E), except for patient 5, who received intramuscular vitamin B₁₂ injections. None of the patients experienced cognitive improvement with supplementation alone, despite confirmed normalization of serum vitamin B₁₂ and folate levels. Paraneoplastic antibodies were absent in all 5 patients (patients 4-6, 8, and 9) tested.

FOLLOW-UP

During follow-up, 10 patients deteriorated cognitively and 9 died of complications associated with their progressive dementia. Among the patients who deteriorated, the mean duration of disease was 5.9 years after the onset of cognitive impairment (median, 6 years; range, 1-11 years). Four patients (patients 2, 7, 8, and 12) underwent repeat small-bowel biopsies that showed partially treated CD, and 5 (patients 5, 6, 10, 11, and 13) had persistent gastrointestinal symptoms. Two patients improved cognitively with a gluten-free diet: 1 (patient 9) remained cognitively stable for 10 years until he developed probable Alzheimer disease, and the other (patient 3) remained stable for 10 years until he gave up his dietary restrictions. One patient (patient 4) remained neurologically stable with her cognitive deficits and ataxia 6 months

after gluten withdrawal. The gastrointestinal and cognitive symptoms of patient 6 improved transiently while providing total parenteral nutrition, but again declined with increased oral intake. Only 1 patient (patient 7) was treated with plasma exchange, but the patient's condition failed to improve.

NEUROPATHOLOGICAL FINDINGS

Histological analysis of the brain tissue from the 2 patients (patients 2 and 7) who underwent brain biopsy showed only nonspecific gliosis. A comprehensive histological analysis of 2 patients (patients 1 and 6) who underwent postmortem examination also showed evidence of only gliosis in the patients (**Figure 2**). Patient 8 had diffuse gliosis in addition to the presence of τ - and α -synuclein-negative, but ubiquitin-positive, inclusions in the frontal and temporal cortices and hippocampal dentate granular cell layer, in keeping with a pathological diagnosis of frontotemporal lobar degeneration with ubiquitin-only immunoreactive changes.¹¹

In 1 patient (patient 7) who underwent a brain biopsy, brain tissue was surgically implanted in a primate to rule out transmissible prion disease; the result was negative. The brain of patient 6 was additionally examined at the National Prion Disease Pathology Surveillance Center, and prion disease was ruled out. In all 5 patients, Biel-

schowsky silver stain, τ , neurofilament, α -synuclein, and prion immunohistochemistry results were negative.

COMMENT

We describe 13 patients with concurrent onset of cognitive impairment and adult-onset CD. Most of these patients had common neurological complications of CD, such as ataxia and seizure, suggesting a possible link, direct or indirect, between CD and cognitive decline. While the first consideration for the cause of cognitive impairment may be nutritional deficiencies, the absence of any neurological improvement or stabilization after supplementation, and demonstrated normalization in some patients, argues against nutritional deficiency as the sole cause of the encephalopathy. On the contrary, 3 patients had at least stabilization, with significant improvement in 2, of their cognitive deficits with gluten withdrawal, similar to others' experience.^{6,7} However, the strongest arguments for an association between the cognitive impairment and CD are the close temporal relationship between the onset of CD-associated gastrointestinal and cognitive symptoms and the constellation of other CD-associated neurological symptoms. It seems more than mere coincidence that in 5 patients the onset of CD and cognitive impairment was simultaneous.

A total of 13 patients have been previously described as having cognitive decline associated with CD. Cooke and Smith² first described a dementia-like syndrome in 2 patients with childhood-onset CD. More recently, Collin et al⁵ described 5 patients with adult-onset CD, dementia, and brain atrophy. Four of these patients demonstrated general slowing on EEG, similar to ours, and 3 had spike-and-wave discharges. By combining our series with theirs, only 1 of 14 patients with CD and cognitive impairment had a normal-appearing EEG. Nevertheless, no EEG finding was characteristic among all patients, other than nonspecific slowing. Findings of confluent periventricular changes and discrete foci on MRI were equally nonspecific, but both have been observed in 10 patients with CD who experienced headaches¹² and in 1 patient with cognitive changes.⁷ Thalamic involvement has also been described,¹² suggesting that it may be more common than the frequency of 1 in 13 we observed.

The mechanism of cognitive impairment remains elusive in CD. Patients with CD and ataxia but no cognitive complaints did poorer on neuropsychological testing than age- and sex-matched control subjects,¹³ suggestive of a chronic neuropathological process. Neuropsychometric testing in our patients always revealed involvement of frontosubcortical networks, although in 3 patients other domains were also affected. A larger cohort of patients with a more consistent battery is necessary to generalize this finding. Pathologically, Kinney et al⁴ provided the only detailed autopsy study of a patient who developed CD and dementia at the age of 55 years. Similar to 4 of our patients with histological studies, the only remarkable finding was nonspecific gliosis in the subcortical and deep white matter. Folate, vitamin B₁₂, and vitamin E deficiencies have all been identified in patients




Figure 2. Areas of widespread gliosis in a biopsy specimen taken from patient 7 (original magnification $\times 5$). The inset shows high-power staining of astrocytes with anti-gial fibrillary acid protein antibodies (original magnification $\times 40$).

with dementia suspected to be associated with CD. Yet, supplementation invariably failed to stabilize or reverse the cognitive decline. Thus, such nutritional deficiency is likely a consequence of malabsorption associated with CD enteropathy, but deficiency in a yet unidentified micronutrient⁵ remains a plausible explanation.

Autoimmunity involving the central nervous system is another possible mechanism. Hadjivassiliou and co-workers demonstrated strong staining of healthy human Purkinje cells¹⁴ and targeting of tissue transglutaminase in brain specimens¹⁵ by serum samples from patients with gluten-related ataxia. The involvement of tissue transglutaminase antibody in cognitive impairment may be supported clinically by the positive titer in our patients and the titer elevation along the progressive decline in patient 4. Last, a chance occurrence of CD and a yet unidentified progressive cognitive decline remain possible. Celiac disease is highly prevalent in the general population, occurring at 0.75%,¹⁶ and pathological examination in 1 of the patients demonstrated findings of frontotemporal lobar degeneration with ubiquitin-only immunoreactive changes. We speculate that this was a coincidence, but further studies looking for clinical features of CD in patients with frontotemporal lobar degeneration and ubiquitin staining in the brain specimens of patients with antemortem CD will be necessary before we come to a final conclusion. Nevertheless, the simultaneous onset of cognitive impairment and CD in patients with similar clinical profiles would make mere chance occurrence rather unlikely.

Not unexpectedly, cognitive impairment associated with CD was never the initial clinical diagnosis, although it was later diagnosed in some. The lack of uniform response to gluten withdrawal was likely complicated by compliance, because noncompliance and biopsy-proved evidence of only partial treatment were common. We were surprised at the fact that CJD was considered a likely diagnosis in almost a third of the patients. A prion disease was a reasonable consideration given the presenting signs of subacute dementia, ataxia,

myoclonus, and seizure, and, in 2 patients, an elevated neuron-specific enolase level. In 1 patient in whom CJD was suspected, MRI of the head further revealed asymmetrically increased T2 changes in the anterior and pulvinar regions of the thalamus. While the symmetric "pulvinar sign" is associated with variant CJD, an asymmetric pulvinar sign is uncommon.¹⁷ Hence, we suggest that a workup for CD and possibly gluten withdrawal be at least considered in patients with CJD.

In summary, we provide a more detailed report on the possible association between CD and cognitive impairment than previous series. While we hypothesize on the association and the causative pathogenesis, the fact remains that some of our patients did respond to gluten withdrawal. With nearly half of brain biopsy specimens lacking specific features to aid in the diagnosis of dementia in 1 recent series,¹⁸ a reevaluation of the role of CD in causing cognitive impairment has the potential of expanding the narrow spectrum of the treatable dementia.

Accepted for Publication: March 20, 2006.

Correspondence: Keith A. Josephs, MST, MD, Department of Neurology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905 (josephs.keith@mayo.edu).

Author Contributions: *Study concept and design:* Hu, Murray, and Josephs. *Acquisition of data:* Hu and Parisi. *Analysis and interpretation of data:* Hu, Murray, Greenaway, and Parisi. *Drafting of the manuscript:* Hu, Murray, and Josephs. *Critical revision of the manuscript for important intellectual content:* Hu, Murray, Greenaway, Parisi, and Josephs. *Administrative, technical, and material support:* Hu and Parisi. *Study supervision:* Murray and Josephs.

Funding/Support: This study was supported in part by grant R01-DK 57892 from the National Institutes of Health (Dr Murray); by Roadmap Multidisciplinary Clinical Research Career Development Award grant (K12/NICHD)-HD49078 from the National Institutes of Health (Dr Josephs); and by the Robert H. and Clarice Smith and Abigail Van Buren Alzheimer's Disease Research Programs of the Mayo Foundation (Dr Josephs).

Acknowledgment: We thank Richard Sloop, MD, for additional information on patient 6.

REFERENCES

1. Holmes GKT. *Neurological and Psychiatric Complications in Celiac Disease*. London, England: John Libbey; 1997.
2. Cooke WT, Smith WT. Neurological disorders associated with adult coeliac disease. *Brain*. 1966;89:683-722.
3. Hadjivassiliou M, Grunewald RA, Davies-Jones GA. Gluten sensitivity as a neurological illness. *J Neurol Neurosurg Psychiatry*. 2002;72:560-563.
4. Kinney HC, Burger PC, Hurwitz BJ, Hijmans JC, Grant JP. Degeneration of the central nervous system associated with celiac disease. *J Neurol Sci*. 1982;53:9-22.
5. Collin P, Pirttila T, Nurmikko T, Somer H, Eriola T, Keyrilainen O. Celiac disease, brain atrophy, and dementia. *Neurology*. 1991;41:372-375.
6. Luostarinen L, Pirttila T, Collin P. Coeliac disease presenting with neurological disorders. *Eur Neurol*. 1999;42:132-135.
7. Siqueira Neto JI, Costa AC, Magalhaes FG, Silva GS. Neurological manifestations of celiac disease. *Arq Neuropsiquiatr*. 2004;62:969-972.
8. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)*. Washington, DC: American Psychiatric Association; 2000.
9. Kokmen E, Smith GE, Petersen RC, Tangalos E, Ivnick RC. The Short Test of Mental Status: correlations with standardized psychometric testing. *Arch Neurol*. 1991; 48:725-728.
10. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res*. 1975; 12:189-198.
11. Josephs KA, Holton JL, Rossor MN, et al. Frontotemporal lobar degeneration and ubiquitin immunohistochemistry. *Neuropathol Appl Neurobiol*. 2004;30: 369-373.
12. Hadjivassiliou M, Grunewald RA, Lawden M, Davies-Jones GA, Powell T, Smith CM. Headache and CNS white matter abnormalities associated with gluten sensitivity. *Neurology*. 2001;56:385-388.
13. Burk K, Bosch S, Muller CA, et al. Sporadic cerebellar ataxia associated with gluten sensitivity. *Brain*. 2001;124:1013-1019.
14. Hadjivassiliou M, Boscolo S, Davies-Jones GA, et al. The humoral response in the pathogenesis of gluten ataxia. *Neurology*. 2002;58:1221-1226.
15. Hadjivassiliou M, Maki M, Sanders DS, et al. Autoantibody targeting of brain and intestinal transglutaminase in gluten ataxia. *Neurology*. 2006;66:373-377.
16. Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. *Arch Intern Med*. 2003;163:286-292.
17. Zeidler M, Sellar RJ, Collie DA, et al. The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease. *Lancet*. 2000;355:1412-1418.
18. Warren JD, Schott JM, Fox NC, et al. Brain biopsy in dementia. *Brain*. 2005;128: 2016-2025.

Announcement

Sign Up for Alerts—It's Free! *Archives of Neurology* offers the ability to automatically receive the table of contents of ARCHIVES when it is published online. This also allows you to link to individual articles and view the abstract. It makes keeping up-to-date even easier! Go to <http://pubs.ama-assn.org/misc/alerts.dtl> to sign up for this free service.